José Gatell, MD, and Anton L. Pozniak, MD, FRCP, discuss the latest European guidelines on initial antiretroviral therapy and review new data that help define the efficacy of initial regimens.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the optimal timing of first-line antiretroviral therapy
- Summarize the data supporting the preferred and alternative antiretroviral regimens in the current European guidelines
- Describe the role of novel agents in first-line antiretroviral therapy
Abstract